Vizgen vs Tempus

Side-by-side comparison of AI visibility scores, market position, and capabilities

Tempus leads in AI visibility (74 vs 35)
Vizgen logo

Vizgen

EmergingLife Sciences & BioTech

Spatial Genomics & Single-Cell Transcriptomics

Vizgen is a Cambridge MA life sciences company commercializing MERSCOPE, a spatial genomics platform based on MERFISH technology licensed from Harvard; enables single-cell, subcellular-resolution RNA imaging in intact tissue;

AI VisibilityBeta
Overall Score
D35
Category Rank
#126 of 198
AI Consensus
87%
Trend
stable
Per Platform
ChatGPT
33
Perplexity
37
Gemini
37

About

Vizgen is a life sciences company founded in 2019 and headquartered in Cambridge, Massachusetts, that has commercialized the MERSCOPE platform — a spatial genomics instrument based on MERFISH (Multiplexed Error-Robust Fluorescence In Situ Hybridization) technology originally developed in the lab of Xiaowei Zhuang at Harvard University. MERSCOPE enables researchers to simultaneously measure the expression of hundreds to thousands of genes in individual cells while preserving the spatial location of those cells within intact tissue samples. This combination of single-cell resolution and spatial context is a significant advance over traditional bulk RNA sequencing (which loses spatial information) and earlier single-cell sequencing methods (which require tissue dissociation that destroys spatial architecture).

Full profile
Tempus logo

Tempus

LeaderLife Sciences & BioTech

AI-Enabled Precision Medicine

Publicly traded AI precision medicine company (Nasdaq: TEM); $1.27B revenue in 2025 (+83% YoY); $14B+ market cap; genomic profiling, algorithmic diagnostics, and clinical trial matching across oncology, neurology, and cardiology.

AI VisibilityBeta
Overall Score
B74
Category Rank
#11 of 198
AI Consensus
68%
Trend
stable
Per Platform
ChatGPT
71
Perplexity
68
Gemini
80

About

Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder of Groupon) and headquartered in Chicago, Illinois, Tempus built the world's largest library of clinical and molecular data and applies AI to help physicians make more personalized, data-driven treatment decisions. The company's core offerings include genomic profiling (sequencing tumor DNA to identify mutations and actionable targets), algorithmic diagnostic tests (AI-driven companion diagnostics for cancer treatment selection), clinical trial matching (connecting eligible patients to appropriate studies), and data licensing to pharmaceutical and biotech partners for drug discovery and clinical development.

Full profile

AI Visibility Head-to-Head

35
Overall Score
74
#126
Category Rank
#11
87
AI Consensus
68
stable
Trend
stable
33
ChatGPT
71
37
Perplexity
68
37
Gemini
80
38
Claude
77
38
Grok
69

Key Details

Category
Spatial Genomics & Single-Cell Transcriptomics
AI-Enabled Precision Medicine
Tier
Emerging
Leader
Entity Type
brand
brand

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.